Matthew Plavan
2008 - Cesca Therapeutics
In 2008, Matthew Plavan earned a total compensation of $464K as CFO & EVP, Business Development at Cesca Therapeutics, a 65% increase compared to previous year.
Compensation breakdown
| Option Awards | $225,000 |
|---|---|
| Salary | $233,000 |
| Other | $6,000 |
| Total | $464,000 |
Plavan received $233K in salary, accounting for 50% of the total pay in 2008.
Plavan also received $225K in option awards and $6K in other compensation.
Rankings
In 2008, Matthew Plavan's compensation ranked 6,747th out of 9,135 executives tracked by ExecPay. In other words, Plavan earned more than 26.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,747 out of 9,135 | 26th |
Division Manufacturing | 2,508 out of 3,436 | 27th |
Major group Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks | 352 out of 517 | 32nd |
Industry group Laboratory Apparatus And Analytical, Optical, Measuring, and Controlling Instruments | 128 out of 194 | 34th |
Industry Laboratory Apparatus and Furniture | 2 out of 4 | 50th |
Source: SEC filing on October 26, 2010.
News
Arcadia Biosciences CEO Matthew Plavan's 2021 pay jumps 102% to $1.6M
April 19, 2022
Arcadia Biosciences CEO Matthew Plavan's 2020 pay jumps 37% to $794K
April 20, 2021
Arcadia Biosciences CEO Matthew Plavan's 2019 pay stays at $581K
April 17, 2020
Arcadia Biosciences CEO Rajendra Ketkar's 2018 pay jumps 40% to $904K
April 18, 2019